Compare POST & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POST | GRFS |
|---|---|---|
| Founded | 1895 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.9B |
| IPO Year | 2011 | N/A |
| Metric | POST | GRFS |
|---|---|---|
| Price | $88.63 | $7.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $124.50 | $10.15 |
| AVG Volume (30 Days) | ★ 789.9K | 718.4K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.28 | N/A |
| Revenue | ★ $8,158,100,000.00 | N/A |
| Revenue This Year | $4.93 | $4.49 |
| Revenue Next Year | $0.47 | $6.42 |
| P/E Ratio | $26.98 | ★ $18.67 |
| Revenue Growth | ★ 2.97 | N/A |
| 52 Week Low | $86.37 | $6.96 |
| 52 Week High | $116.35 | $11.14 |
| Indicator | POST | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 40.35 |
| Support Level | $86.61 | N/A |
| Resistance Level | $108.07 | $7.73 |
| Average True Range (ATR) | 2.71 | 0.16 |
| MACD | 0.31 | 0.00 |
| Stochastic Oscillator | 29.94 | 34.06 |
Post Holdings Inc. is a consumer packaged goods holding company with products sold through grocery, club, and drug stores, mass merchandisers, foodservice, food ingredient, and eCommerce. It operates through four reportable segments: Post Consumer Brands, focused on North American ready-to-eat cereal and granola, pet food, and nut butters; Weetabix, focused on U.K. ready-to-eat cereal, muesli, and protein-based shakes; Foodservice, focused on egg and potato products; and Refrigerated Retail, focused on side dish, egg, cheese, and sausage products. Products are sold across channels, including retailers, wholesalers, convenience stores, pet supply retailers, drug store customers, military and national restaurant chains, with revenues largely generated in the U.S.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.